We present a case of a man diagnosed with systemic lupus erythematosus, associated antiphospholipid syndrome and Evans syndrome, who developed a severe thrombocytopenia refractory to treatment with first-line drugs, cyclophosphamide and rituximab, and who responded to romiplostim with a normalization of the platelet recount, which later enabled a therapeutic splenectomy to be performed.
EvansRSTakahashiKDuaneRTPayneRLiuC. Primary thrombocytopenic purpura and acquired haemolytic anemia; evidence for a common etiology. AMA Arch Intern Med1951; 87: 48–65.
2.
NortonARobertsI. Management of Evans syndrome. Br J Haematol2006; 132: 125–137.
3.
KotbRPinganaudCTrichetC. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur J Haematol2005; 75: 60–64.
4.
ScaradavouABusselJ. Evans syndrome. Results of a pilot study utilizing a multiagent treatment protocol. J Pediatr Hematol Oncol1995; 17: 290–295.
5.
WilliamsJABoxerLA. Combination therapy for refractory idiopathic thrombocytopenic purpura in adolescents. J Pediatr Hematol Oncol2003; 25: 232–235.
6.
SuarezIMDiazRAAguayo-CanelaDPujol de la LlaveE. Correction of severe thrombocytopenia with chloroquine in the primary antiphospholipid syndrome. Lupus1996; 5: 81–83.
7.
MantadakisEDanilatouVStiakakiEKalmantiM. Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases. Am J Hematol2004; 77: 303–310.
8.
RückertAGlimmHLübbertMGrüllichC. Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: a case with long-term follow-up. Lupus2008; 17: 757–760.
9.
BusselJBKuterDJGeorgeJN. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med2006; 355: 1672–1681.
10.
WangBNicholJLSullivanJT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther2004; 76: 628–638.
11.
NewlandACaulierMTKappers-KlunneM. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol2006; 135: 547–553.
12.
KuterDJBusselJBLyonsRM. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet2008; 371: 395–403.
13.
GeorgeJNMathiasSDGoRS. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol2009; 144: 409–415.
14.
KantarjianHFenauxPSekeresMA. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol2010; 28: 437–444.
15.
PerreaultSBurzynskiJ. Romiplostim: a novel thrombopoiesis-stimulating agent. Am J Health Syst Pharm2009; 66: 817–824.
